Paul Kinnon, an analytical chemist, has been appointed chief executive of PredictImmune Ltd of the UK which is developing prognostic biomarkers for informing the treatment of immune-mediated diseases. Mr Kinnon has been an executive at Transgenomic (now Precipio Inc) Diagnostics LLC), ZyGEM Corp and Life Technologies (now Thermo Fisher Scientific Inc). He is a graduate of Coventry University in the UK and did entrepreneurial studies at the MIT Sloan School of Management in the US.
PredictImmune announced the appointment on 2 July 2018.
Evernow Publishing Ltd 2018.